Print

Print


Commission highlights initiatives to fight Parkinson's disease

Date: 2003-04-11

Marking world Parkinson's disease day on 11 April, the European
Commission is highlighting the results of two EU funded projects
aimed at improving research into the disease and the rehabilitation
of sufferers.

The PARREHA (Parkinsonians rehabilitation) project is designed to
help patients overcome their symptoms through visual and audio
stimuli, while the EuroPa (European cooperative network for research,
diagnosis and therapy of Parkinson's disease) aims to improve
understanding and treatment of Parkinson's through the networking of
clinical centres in various European countries.

EU Commissioner for Research, Philippe Busquin, highlighted the
potential contribution of the two projects: 'EU research can help to
improve the quality of life of people affected by this debilitating
disorder. The creation of research networks allows the pooling of
Europe's best scientists to reach real breakthroughs in finding
solutions for this disease.'

Parkinson's disease currently affects over 500,000 Europeans, and the
proportion of sufferers is continually growing due to the aging of
the population as a whole. As well as the obvious medical problems
associated with the condition, it is also one of the most costly
brain disorders known, with a German study suggesting that annual
therapy costs total around 6,000 euro per patient.

Parkinson's disease is a movement dysfunction. The PARREHA project,
supported by 1.7 million euro under the IST section of the Fifth
Framework Programme (FP5) and co funded by the Commission's Joint
Research Centre (JRC), has developed a set of information technology
tools to assist the rehabilitation of Parkinson's patients suffering
mobility problems.

Audio and visual stimulation has been known to suddenly relieve
sufferers of all their symptoms, a phenomenon known as 'Kinesia
Paradoxa' and still not completely understood. Through the use of
personalised virtual reality glasses, virtual exercise and training
systems, and personalised remote consultation, the PARREHA project
has developed tools that can significantly improve on the results of
traditional rehabilitation methods.

Prototypes of the PARREHA system have shown impressive results in
helping lethargic patients become significantly more active, and the
project consortium are now aiming to market the results on a
commercial basis.

The EuroPa network is an association of clinical centres from 11
countries (Austria, the Czech Republic, France, Germany, Israel,
Italy, Portugal, Spain, Sweden, the Netherlands and the UK) and was
set up with 1.7 million euro in funding under the Life Quality
section of FP5.

The main aim of the network is the creation of a clinical trials
network using Internet technology, which will establish a central
patient registry to help find patients who fit the necessary clinical
profile for a particular trial. Medical information will be stored
under pseudonyms to protect patient privacy, and by combining the
knowledge and resources of all project partners in a database of
precise medical information will speed up and improve research into
Parkinson's.

After the end of the initial EU funding period, which is due to end
in September 2004, the network will be transformed into a self
sufficient and independent organisation. Specialists from other
clinics and European countries will then be able to join the network
and increase its scope and collaboration.

The Commission intends to fund more projects focussing on brain
research under the Sixth Framework Programme, with conditions such as
Parkinson's and Alzheimer's a high priority. Mr Busquin also
announced the Commission's intention, along with the European
Parliament, to organise a conference to discuss how to build a 'true
European Brain Research Area'.

For further information, please consult the following web address:
http://www.parreha.com
http://www.europarkinson.net
http://www.cordis.lu/lifescihealth

SOURCE: CORDIS RTD-NEWS
http://dbs.cordis.lu/cgi-
bin/srchidadb?CALLER=NHP_EN_NEWS&ACTION=D&SESSION=&RCN=EN_RCN_ID:20077

* * *

----------------------------------------------------------------------
To sign-off Parkinsn send a message to: mailto:[log in to unmask]
In the body of the message put: signoff parkinsn